VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA

这些研究人员提议对VH区域进行克隆和测序 从新鲜的淋巴组织中提取淋巴瘤相关免疫球蛋白 复发性淋巴瘤患者。他们将选择一个25聚体的多肽序列 来自VH区，基于其包含9个具有最佳MHC多肽的MERS 使用基于预测的生物信息学方法的结合容量 为患者表达的特定的HLA-1等位基因建立的结合基序。 该多肽将被合成并用于对富集树突状细胞进行“脉冲” 通过Flt-3配体处理体内产生的外周血液。 他们预计体内的多个抗原提呈细胞群 DC外周血将处理并呈递广泛的抗原 MHC I类背景导致产生广泛的CD8T细胞应答 抗肿瘤相关免疫球蛋白，因此，肿瘤。他们 预计在两年内每年评估五名患者。他们将决定 外周血树突状细胞体内生成的安全性和可行性 血液在这个患者群体中，他们将决定安全性和 肿瘤VH肽致敏树突状细胞免疫的可行性 肿瘤VH多肽疫苗的临床和免疫学反应 淋巴瘤患者外周血中的致敏DC。

These investigators propose to clone and sequence the VH regions from lymphoma-associated immunoglobulin from fresh lymph node tissue from patients with recurrent lymphoma. They will chose a peptide sequence of 25-mer from the VH region based on its inclusion of 9 mers having optimal MHC peptide binding capacity using a bio-informatics approach based on predictions using binding motifs established for specific HLA-1 alleles expressed by the patient. The peptide will be synthesized and used to "pulse" dendritic cells enriched from the peripheral blood generated in vivo by treatment with FLT-3 ligand. They anticipate that the multiple antigen presenting cell populations within the DC peripheral blood will process and present a wide spectrum of antigens in the context of MHC class I leading to a broad CD8 + T cell response generated against tumor-associated immunoglobulin, and therefore, the tumor. They anticipate evaluating five patients per year for two years. They will determine the safety and feasibility of the in vivo generation of DC from peripheral blood in this patient population, they will determine the safety and feasibility of vaccination with tumor VH peptide pulsed DC, and determine the clinical and immunologic response of vaccination with the tumor VH peptide pulsed DC from peripheral blood from patients with lymphoma.